about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Bay­er rolls out big changes; 2024's biotech IPO queue; Dupix­en­t's 'next big thing'; 23and­Me's strug­gle with dual ...

Last year
Weekly

As­traZeneca reshuf­fles Chi­na lead­er­ship, sets up bio­phar­ma group to mir­ror glob­al struc­ture

Last year
People
China

Up­dat­ed: Vivek Ra­maswamy gives up pres­i­den­tial bid, en­dors­es Trump, no plans to re­turn to Roivant

Last year
People

Four buy­outs (and one ru­mor that didn’t ma­te­ri­al­ize); Iso­mor­phic Lab­s' first phar­ma deals; A CAR-T IPO; #JPM24 ...

Last year
Weekly

C4 Ther­a­peu­tics cuts staff, re­struc­tures to fo­cus on lead pro­tein degra­da­tion pro­grams, dis­cov­ery pacts

Last year
People
R&D

Al­con touts PhI­II win for dry eye drug, plans mid-2024 FDA fil­ing

Last year
R&D

TG li­cens­es Pre­ci­sion's cell ther­a­py; In­noven­t's PhI­II weight loss win; Atea's pos­i­tive hep C da­ta

Last year
News Briefing

Blue­print to pull Gavre­to in cer­tain mar­kets, shelve EGFR pro­grams as it fo­cus­es on Ay­vak­it launch

Last year
R&D

Sen­ti Bio cuts 37% of staff; Evotec pock­ets $25M mile­stone from BMS; No­var­tis buys San­Reno

Last year
News Briefing

Bay­er’s $425M non-hor­mon­al ther­a­py for menopause symp­toms clears first PhI­II test

Last year
R&D

Mer­ck brings Har­poon Ther­a­peu­tics and its PhI/II T cell en­gager in­to the fold for $680M

Last year
Deals

No­var­tis strikes $250M buy­out for Mer­ck Serono spin­out's au­toim­mune 'pipeline-in-a-drug'

Last year
Deals

Roche leads pre-JPM deal spree; Roger Perl­mut­ter’s new phar­ma force; In­side Sage’s big tri­umph and fail­ure; Late ...

Last year
Weekly

Al­lo­gene Ther­a­peu­tics plans re­struc­tur­ing as it swaps out PhII CAR-T tri­al plans to leapfrog ri­vals

Last year
R&D
Cell/Gene Tx

Trail­ing No­var­tis and Eli Lil­ly, ra­dio­phar­ma­ceu­ti­cals start­up Full-Life Tech­nolo­gies nabs $63M to test new PS­MA drug

Last year
Financing
China

Re­gen­eron scores Eylea patent win against My­lan, keep­ing biosim­i­lar at bay

Last year
Pharma
Law

AlloVir to wind down PhI­II tri­als for fu­til­i­ty and will re­view strate­gic al­ter­na­tives

Last year
R&D

Ab­b­Vie's $10B Im­muno­Gen deal was won by pay­ing $7 a share over a ri­val bid­der's of­fer, SEC fil­ings show

Last year
Deals

Bio­Marin strikes co­op­er­a­tion deal with ac­tivist in­vestor El­liott, sets up re­view com­mit­tee and adds board mem­bers

Last year
People
Pharma

Sanofi pulls the plug on ADC af­ter lung can­cer PhI­II dis­ap­points

Last year
R&D

Aclaris halves head­count, banks on next mid-stage read­out af­ter clin­i­cal set­backs tanked shares

Last year
People

Blue­bird in fundrais­ing mode: A $150M pub­lic of­fer­ing and a deal to get cash ear­ly from gene ther­a­py sales

Last year
Financing
Deals

Pfiz­er's tur­moil; FTC's new tar­get; Aviv Regev Q&A; As­traZeneca's vac­cine gam­bit; Best of #ASH23; and more

Last year
Weekly

Pfiz­er picks up ear­ly-stage ADC can­di­date cleared for sol­id tu­mor tri­als

Last year
Deals
First page Previous page 3456789 Next page Last page
A service from the Financial Times